MA31366B1 - Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2 - Google Patents

Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2

Info

Publication number
MA31366B1
MA31366B1 MA32331A MA32331A MA31366B1 MA 31366 B1 MA31366 B1 MA 31366B1 MA 32331 A MA32331 A MA 32331A MA 32331 A MA32331 A MA 32331A MA 31366 B1 MA31366 B1 MA 31366B1
Authority
MA
Morocco
Prior art keywords
azitidine
prostaglandins
derivatives
relates
antagonist
Prior art date
Application number
MA32331A
Other languages
Arabic (ar)
English (en)
Inventor
Kevin Neil Dack
Siew Kuen Yeap
Sarah Elizabeth Skerratt
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA31366B1 publication Critical patent/MA31366B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une classe d'azétidines antagonistes des ep-2 de formule générale (i) où les variables et groupes substituants sont comme définis dans la description, et concerne en particulier les composés antagonistes des ep-2, leur utilisation en médecine, en particulier dans le traitement de l'endométriose et/ou des fibromes utérins (léiomyomatose) et les intermédiaires utiles dans leur synthèse et les compositions les contenant.
MA32331A 2007-05-10 2009-11-10 Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2 MA31366B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91708107P 2007-05-10 2007-05-10
US1303007P 2007-12-12 2007-12-12
PCT/IB2008/001070 WO2008139287A1 (fr) 2007-05-10 2008-04-28 Dérivés d'azétidine et leur utilisation comme antagonistes des prostaglandines e2

Publications (1)

Publication Number Publication Date
MA31366B1 true MA31366B1 (fr) 2010-05-03

Family

ID=39739736

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32331A MA31366B1 (fr) 2007-05-10 2009-11-10 Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2

Country Status (27)

Country Link
US (1) US20080280877A1 (fr)
EP (1) EP2155666A1 (fr)
JP (1) JP2010526801A (fr)
KR (1) KR20100009582A (fr)
CN (1) CN101679235A (fr)
AP (1) AP2009005047A0 (fr)
AR (1) AR066524A1 (fr)
AU (1) AU2008249744A1 (fr)
BR (1) BRPI0811444A2 (fr)
CA (1) CA2686517A1 (fr)
CL (1) CL2008001305A1 (fr)
CO (1) CO6260066A2 (fr)
CR (1) CR11101A (fr)
DO (1) DOP2009000256A (fr)
EA (1) EA200901381A1 (fr)
EC (1) ECSP099727A (fr)
GT (1) GT200900293A (fr)
IL (1) IL201874A0 (fr)
MA (1) MA31366B1 (fr)
MX (1) MX2009011998A (fr)
PA (1) PA8779601A1 (fr)
PE (1) PE20090282A1 (fr)
SV (1) SV2009003407A (fr)
TN (1) TN2009000470A1 (fr)
TW (1) TW200904409A (fr)
UY (1) UY31070A1 (fr)
WO (1) WO2008139287A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256109A1 (en) * 2007-11-15 2010-10-07 Sarah Elizabeth Skerratt Azetidines As EP2 Antagonists
PE20110663A1 (es) * 2008-11-10 2011-09-23 Pfizer Ltd Pirrolidinas
WO2010114997A1 (fr) * 2009-04-02 2010-10-07 Allergan, Inc. Antagonistes du récepteur de la prostaglandine e
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
WO2013010679A1 (fr) 2011-07-15 2013-01-24 Novartis Ag Sels d'éthers diaryliques aza-bicycliques et procédés pour fabriquer ceux-ci ou leurs précurseurs
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
EP3237401B1 (fr) 2014-12-22 2019-03-06 Pfizer Inc Antagonistes de récepteur ep3 de prostaglandine
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
US12703680B2 (en) 2019-11-21 2026-08-11 University Of Utah Research Foundation TRPV4 receptor ligands
JP2024524986A (ja) 2021-06-24 2024-07-09 レザボア ニューロサイエンス，インコーポレイテッド Ｅｐ２アンタゴニスト化合物
EP4359399A4 (fr) * 2021-06-24 2025-04-23 Reservoir Neuroscience, Inc. Composés antagonistes d'ep2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8300860D0 (en) * 1983-01-13 1983-02-16 Shell Int Research Azetidine compounds
GB8415614D0 (en) * 1984-06-19 1984-07-25 Shell Int Research Azetidine derivatives
GB8509746D0 (en) * 1985-04-16 1985-05-22 Shell Int Research Preparing azetidine derivatives
AR037364A1 (es) 2001-11-16 2004-11-03 Schering Corp Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
NZ567140A (en) * 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives

Also Published As

Publication number Publication date
SV2009003407A (es) 2010-01-12
CA2686517A1 (fr) 2008-11-20
DOP2009000256A (es) 2009-11-30
TW200904409A (en) 2009-02-01
MX2009011998A (es) 2009-11-19
CL2008001305A1 (es) 2008-07-18
JP2010526801A (ja) 2010-08-05
EP2155666A1 (fr) 2010-02-24
EA200901381A1 (ru) 2010-06-30
WO2008139287A1 (fr) 2008-11-20
CN101679235A (zh) 2010-03-24
IL201874A0 (en) 2010-06-16
ECSP099727A (es) 2009-12-28
US20080280877A1 (en) 2008-11-13
CO6260066A2 (es) 2011-03-22
PE20090282A1 (es) 2009-03-27
AU2008249744A1 (en) 2008-11-20
AR066524A1 (es) 2009-08-26
TN2009000470A1 (fr) 2011-03-31
UY31070A1 (es) 2009-01-05
KR20100009582A (ko) 2010-01-27
BRPI0811444A2 (pt) 2014-10-29
PA8779601A1 (es) 2009-01-23
AP2009005047A0 (en) 2009-12-31
GT200900293A (es) 2010-05-17
CR11101A (es) 2009-12-04

Similar Documents

Publication Publication Date Title
TN2009000470A1 (fr) Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2
MA33832B1 (fr) Isoquinolinones et quinazolinones substituées
MA35576B1 (fr) Nouveaux composés
MA30228B1 (fr) Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
ATE538099T1 (de) 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA31447B1 (fr) Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
EA201190302A1 (ru) ПРОИЗВОДНЫЕ 7-АРИЛ-1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
MXPA05011166A (es) Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA39043A1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
MA30514B1 (fr) Nouveaux composes.